Navigation Links
EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models

ROCKVILLE, Md., June 01, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of preclinical results for its Aurora kinase - angiogenesis inhibitor, ENMD-981693. The data were presented during oral and poster presentations by EntreMed scientists at the 2nd Protein Kinases in Drug Discovery Conference being held May 31 - June 1, 2007 in Boston, Massachusetts.

ENMD-981693 is an oral, dual-acting kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. In preclinical studies, ENMD-981693 has been shown to inhibit a unique profile of angiogenic tyrosine kinase targets in addition to the Aurora kinases. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-981693 is selective for the Aurora A isoform in comparison to Aurora B.

Results from in vitro studies demonstrate ENMD-981693's potent activity against oncogenic receptor tyrosine kinases, including FLT3, c-Kit and CSF1R, which are involved in the pathology of hematological cancers. Additionally, ENMD-981693 demonstrated potent inhibition of a spectrum of targets linked to angiogenesis, including KDR (VEGFR2) and FGFR1. The compound was also shown to induce apoptosis and cell cycle arrest in a broad range of cell lines.

ENMD-981693 exhibited antiangiogenic activity in in vivo animal models by preventing the formation of new blood vessels and inducing regression of formed vessels at well-tolerated doses. Orally-administered ENMD-981693 induced tumor regression with minimal toxicity in a preclinical xenograft model of human leukemia. This activity is consistent with tumor regression induced by ENMD-981693 in preclinical models of human tumors derived from colon, leukemia, and breast cancer cell lines.

Mark
'"/>




Page: 1 2 3

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
4. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
5. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
6. AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
7. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
Post Your Comments:
(Date:5/27/2015)... -- Foundation Health Care  (FDNH), which owns and operates hospitals ... it will present at the LD Micro Invitational Conference ... Boulevard Hotel, Los Angeles, CA. ... at 3:00pm and will also be available for ... LD Micro. For more information about the conference, please ...
(Date:5/27/2015)... , May 27, 2015  Genomic Health, Inc. (Nasdaq: ... Operating Officer and Chief Financial Officer, will present at the ... City on Monday, June 1 at 8:30 a.m. ... subsequently archived webcast of the presentation, go to the  Investor ... .  Please connect to the web site at least 15 ...
(Date:5/27/2015)... , May 25, 2015 Research and Markets ... the "Research and Future Development Trend Forecast of ... At present, there are 35,600 dialysis centers ... ratio are large due to the different regional operating ... centers in other Asian countries are operated by state-owned ...
Breaking Medicine Technology:Genomic Health to Present at the Jefferies 2015 Global Healthcare Conference 2Genomic Health to Present at the Jefferies 2015 Global Healthcare Conference 3China Dialysis Market Report: Research and Future Development Trends and Forecasts 2015-2020 2
... 19, 2011 ICAP Patent Brokerage , ... intellectual property brokerage and patent auction firm, is ... major medical device company. The available portfolios disclose ... control, high-intensity focused ultrasound (HIFU) energy, improved blood ...
... SAN DIEGO, Oct. 19, 2011 CareFusion (NYSE: ... following update regarding its recall of 128 EnVe™ ventilators affecting ... Class I recall. The voluntary recall only ... and therefore, has no affect on the company,s current product ...
Cached Medicine Technology:Global Leader in Medical Technology Offers for Sale Seven Patent Portfolios Through ICAP Patent Brokerage 2Global Leader in Medical Technology Offers for Sale Seven Patent Portfolios Through ICAP Patent Brokerage 3CareFusion Initiates Class I Recall of EnVe Ventilators 2
(Date:5/27/2015)... May 27, 2015 NOVAtime Technology, ... Workforce Management solutions for enterprise organizations, announced today ... solution to automate its time, attendance and point ... locations in the United States. , Family-owned ... supplier of 21 retail, private label, and mill ...
(Date:5/27/2015)... 27, 2015 The MedSpa at Hendrick ... dermal filler treatments in Abilene, Texas: Xeomin®, Belotero Balance® ... appearance of glabellar lines, better known as the lines ... is designed to treat smoker’s lines around the mouth ... while Radiesse® improves the appearance of smile lines or ...
(Date:5/27/2015)... IL (PRWEB) May 27, 2015 On ... North-based advertising agency, will partner with LifeSource to host ... event will take place in a LifeSource donor coach ... a.m. to 4:00 p.m. , Demand for whole blood ... in Illinois, during the summer months. LifeSource requires approximately ...
(Date:5/27/2015)... With InnerVoice Communication App you ... message is not only heard but seen -- by a ... motivating image. This award-winning and affordable app takes full advantage ... using InnerVoice Sender app in conjunction with InnerVoice ... learner remotely for no additional cost. , InnerVoice Sender ...
(Date:5/27/2015)... 27, 2015 A television program using ... and Roswell Park Cancer Institute winning ... award-winning story, Cancer Can’t Win , highlights the ... Cancer Institute. The production team followed five people who ... as they received treatment from doctors and medical experts ...
Breaking Medicine News(10 mins):Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:The MedSpa at Hendrick Introduces Xeomin®, Belotero Balance® and Radiesse® Injectables 2Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 3Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 4Health News:MediaSource Wins New York Emmy® Award as Premier Health Care Storytellers 2Health News:MediaSource Wins New York Emmy® Award as Premier Health Care Storytellers 3
... demonstrated for the first time that it is possible to ... Cytomegalovirus (CMV). The virus, which is found in a wide ... tumour growth and reducing the size of the tumour as ... a common virus that is found in 70-75 per cent ...
... Reporter , MONDAY, Sept. 26 (HealthDay News) -- Coffee lovers, take ... daily seem to have a lower risk of depression than those ... a new study suggests. Although it,s way too early to ... the findings may comfort those who feel guilty about their habit. ...
... hormone replacement therapy (HRT) may have an increased risk ... A new study, which will be presented today (27 ... in Amsterdam, adds to the debate over the health ... menopause. Previous studies have found a link ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... cautionary note Monday about an increased risk of blood clots ... as Yaz or Yasmin. Although stopping short of a ... say it "remains concerned" about a potentially higher risk of ...
... Alan Mozes HealthDay Reporter , MONDAY, Sept. 26 ... Dinora Rodriguez. "It was a nightmare." Rodriguez had woken ... not move her arms or even close her eyes. And ... case involving breast implants and a facial scar, gone terribly ...
... Amanda Gardner HealthDay Reporter , MONDAY, Sept. 26 ... with smaller brain size and more problems with thinking skills ... of people who suffer from B-12 deficiencies may be greater ... vitamin may not be accurate, said Christine C. Tangney, lead ...
Cached Medicine News:Health News:Treatment of common virus can reduce tumour growth 2Health News: Lots of Coffee Might Lower Depression Risk: Study 2Health News: Lots of Coffee Might Lower Depression Risk: Study 3Health News:HRT therapy appears to increase risk of hospitalization from severe asthma attacks 2Health News:Newer Contraceptive Pills Could Raise Clot Risk, FDA Warns 2Health News:Check Plastic Surgeon's Credentials or Risk Tragic Results, Experts Warn 2Health News:Check Plastic Surgeon's Credentials or Risk Tragic Results, Experts Warn 3Health News:Check Plastic Surgeon's Credentials or Risk Tragic Results, Experts Warn 4Health News:Could Too Little Vitamin B-12 Shrink the Aging Brain? 2Health News:Could Too Little Vitamin B-12 Shrink the Aging Brain? 3
... VH series, it is a ... independent C-arms and image intensifiers, ... for Cardiovascular and Angiography. There ... the examinations for cerebral, cardiac, ...
This catheter is intended for ultrasound examination of coronary intravascular pathology ONLY. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary i...
Rubidium Rb 82 Generator. ,The only generator-based Positron Emission Tomography agent reimbursed for the evaluation of coronary artery disease....
Kit for the Preparation of Technetium Tc 99m Teboroxime...
Medicine Products: